AR044146A1 - Uso de una toxina botulinica para preparar una composicion farmaceutica de utilidad en un metodo para tratar la cefalea sinusal - Google Patents
Uso de una toxina botulinica para preparar una composicion farmaceutica de utilidad en un metodo para tratar la cefalea sinusalInfo
- Publication number
- AR044146A1 AR044146A1 ARP040101485A ARP040101485A AR044146A1 AR 044146 A1 AR044146 A1 AR 044146A1 AR P040101485 A ARP040101485 A AR P040101485A AR P040101485 A ARP040101485 A AR P040101485A AR 044146 A1 AR044146 A1 AR 044146A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- pharmaceutical composition
- sinusal
- usefulness
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Uso de una toxina botulínica para preparar una composición farmacéutica de utilidad en un método para tratar la cefalea sinusal, que consiste en la administración local de la toxina botulínica a un paciente con cefalea sinusal, y de este modo se trata la cefalea sinusal. La toxina botulínica puede ser tipo A, y la toxina se puede administrar en la membrana sinusal o en un sitio cercano a ella en un paciente con cefalea sinusal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/429,069 US6838434B2 (en) | 2003-05-02 | 2003-05-02 | Methods for treating sinus headache |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044146A1 true AR044146A1 (es) | 2005-08-24 |
Family
ID=33310536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101485A AR044146A1 (es) | 2003-05-02 | 2004-04-30 | Uso de una toxina botulinica para preparar una composicion farmaceutica de utilidad en un metodo para tratar la cefalea sinusal |
Country Status (21)
Country | Link |
---|---|
US (2) | US6838434B2 (es) |
EP (1) | EP1620182B1 (es) |
JP (2) | JP4814086B2 (es) |
KR (1) | KR101057508B1 (es) |
CN (1) | CN1780664A (es) |
AR (1) | AR044146A1 (es) |
AT (1) | ATE446792T1 (es) |
AU (1) | AU2004235743B2 (es) |
BR (1) | BRPI0410041A (es) |
CA (1) | CA2524379C (es) |
CL (1) | CL2004000897A1 (es) |
DE (1) | DE602004023829D1 (es) |
DK (1) | DK1620182T3 (es) |
ES (1) | ES2333017T3 (es) |
HK (1) | HK1087957A1 (es) |
IL (1) | IL171607A (es) |
MX (1) | MXPA05011470A (es) |
PL (1) | PL378982A1 (es) |
TW (1) | TWI323663B (es) |
WO (1) | WO2004098714A1 (es) |
ZA (1) | ZA200508287B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
CA2518157C (en) * | 2003-03-06 | 2018-09-04 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
CA2529528A1 (en) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7922983B2 (en) * | 2005-07-28 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Sterilization wrap with additional strength sheet |
US7811584B2 (en) | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
EP1784420B1 (en) | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
WO2006099590A2 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US7655243B2 (en) * | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
JP5826450B2 (ja) * | 2005-07-22 | 2015-12-02 | ザ ファウンドリー, エルエルシー | 治療薬の送達のためのシステムおよび方法 |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
ES2398052T5 (es) | 2008-05-09 | 2021-10-25 | Nuvaira Inc | Sistemas para tratar un árbol bronquial |
ES2356883B1 (es) * | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | Composición para el tratamiento del dolor y/o la inflamación. |
AU2010315396B2 (en) | 2009-10-27 | 2016-05-05 | Nuvaira, Inc | Delivery devices with coolable energy emitting assemblies |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
EP2498705B1 (en) | 2009-11-11 | 2014-10-15 | Holaira, Inc. | Device for treating tissue and controlling stenosis |
CN102781467A (zh) * | 2009-12-15 | 2012-11-14 | 艾拉·桑德斯 | 鼻和鼻窦失调的治疗 |
US20120244188A1 (en) * | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251574A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
ES2424294B1 (es) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas |
EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
JP6470678B2 (ja) | 2012-04-13 | 2019-02-13 | ルブリゾル アドバンスド マテリアルズ, インコーポレイテッド | ニューロンの開口分泌を阻害する化合物(ii) |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
CN105451710A (zh) | 2013-03-22 | 2016-03-30 | 利普泰股份公司 | 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
CN109790204A (zh) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | 杂合神经毒素 |
US20210187194A1 (en) | 2018-02-26 | 2021-06-24 | Ipsen Biopharm Limited | Use of Ultrasound to Guide Injection of Non-cytotoxic Protease |
EP3908309A1 (en) | 2019-01-07 | 2021-11-17 | Azizzadeh, Babak | Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
WO2023075060A1 (ko) * | 2021-10-25 | 2023-05-04 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물 |
WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
ATE215832T1 (de) * | 1994-05-09 | 2002-04-15 | William J Binder | Botulinumtoxin zur reduktion von migraine - kopfschmerzen |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
ES2268567T5 (es) * | 1997-07-15 | 2010-11-02 | The Regents Of The University Of Colorado | Uso de terapia de neurotoxinas para el tratamiento de la retencion urinaria. |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) * | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6429189B1 (en) * | 1999-12-10 | 2002-08-06 | Botulinum Toxin Research Associates, Inc. | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6649161B1 (en) * | 2000-02-22 | 2003-11-18 | Allergan, Inc. | Method for treating hypocalcemia |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
JP3860403B2 (ja) | 2000-09-25 | 2006-12-20 | 株式会社東芝 | 半導体メモリ装置 |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US20020192239A1 (en) | 2001-01-09 | 2002-12-19 | Borodic Gary E. | Use of botulinum toxin for the treatment of chronic facial pain |
US20020197278A1 (en) | 2001-06-21 | 2002-12-26 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
CA2369810C (en) * | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
CA2518157C (en) * | 2003-03-06 | 2018-09-04 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
WO2004078200A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
-
2003
- 2003-05-02 US US10/429,069 patent/US6838434B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 TW TW093110314A patent/TWI323663B/zh not_active IP Right Cessation
- 2004-04-28 CL CL200400897A patent/CL2004000897A1/es unknown
- 2004-04-30 PL PL378982A patent/PL378982A1/pl not_active Application Discontinuation
- 2004-04-30 CA CA2524379A patent/CA2524379C/en not_active Expired - Fee Related
- 2004-04-30 AT AT04751060T patent/ATE446792T1/de active
- 2004-04-30 DK DK04751060.7T patent/DK1620182T3/da active
- 2004-04-30 AR ARP040101485A patent/AR044146A1/es not_active Application Discontinuation
- 2004-04-30 BR BRPI0410041-7A patent/BRPI0410041A/pt not_active IP Right Cessation
- 2004-04-30 MX MXPA05011470A patent/MXPA05011470A/es active IP Right Grant
- 2004-04-30 KR KR1020057020797A patent/KR101057508B1/ko active IP Right Grant
- 2004-04-30 EP EP04751060A patent/EP1620182B1/en not_active Expired - Lifetime
- 2004-04-30 JP JP2006514187A patent/JP4814086B2/ja not_active Expired - Fee Related
- 2004-04-30 ES ES04751060T patent/ES2333017T3/es not_active Expired - Lifetime
- 2004-04-30 WO PCT/US2004/013480 patent/WO2004098714A1/en active Application Filing
- 2004-04-30 CN CNA2004800116765A patent/CN1780664A/zh active Pending
- 2004-04-30 AU AU2004235743A patent/AU2004235743B2/en not_active Ceased
- 2004-04-30 DE DE602004023829T patent/DE602004023829D1/de not_active Expired - Lifetime
- 2004-11-19 US US10/994,147 patent/US20050152924A1/en not_active Abandoned
-
2005
- 2005-10-13 ZA ZA200508287A patent/ZA200508287B/xx unknown
- 2005-10-27 IL IL171607A patent/IL171607A/en active IP Right Grant
-
2006
- 2006-07-24 HK HK06108209.4A patent/HK1087957A1/xx not_active IP Right Cessation
-
2011
- 2011-04-07 JP JP2011084968A patent/JP2011137042A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20060006956A (ko) | 2006-01-20 |
MXPA05011470A (es) | 2005-12-12 |
US20050152924A1 (en) | 2005-07-14 |
CN1780664A (zh) | 2006-05-31 |
IL171607A (en) | 2016-05-31 |
JP2006525353A (ja) | 2006-11-09 |
CA2524379A1 (en) | 2004-11-18 |
ES2333017T3 (es) | 2010-02-16 |
ZA200508287B (en) | 2007-03-28 |
EP1620182A1 (en) | 2006-02-01 |
TWI323663B (en) | 2010-04-21 |
DE602004023829D1 (de) | 2009-12-10 |
DK1620182T3 (da) | 2010-03-01 |
EP1620182B1 (en) | 2009-10-28 |
JP2011137042A (ja) | 2011-07-14 |
PL378982A1 (pl) | 2006-06-26 |
HK1087957A1 (en) | 2006-10-27 |
AU2004235743A1 (en) | 2004-11-18 |
CL2004000897A1 (es) | 2005-01-07 |
US20040219172A1 (en) | 2004-11-04 |
BRPI0410041A (pt) | 2006-04-25 |
JP4814086B2 (ja) | 2011-11-09 |
ATE446792T1 (de) | 2009-11-15 |
CA2524379C (en) | 2015-03-31 |
KR101057508B1 (ko) | 2011-08-17 |
US6838434B2 (en) | 2005-01-04 |
TW200503751A (en) | 2005-02-01 |
AU2004235743B2 (en) | 2009-10-01 |
WO2004098714A1 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044146A1 (es) | Uso de una toxina botulinica para preparar una composicion farmaceutica de utilidad en un metodo para tratar la cefalea sinusal | |
NO20054988L (no) | Preparater og metoder for behandling av cancer | |
DE60115842D1 (de) | Ventilanordnung | |
WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
AR049955A1 (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos | |
WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
WO2004050033A3 (en) | Method of treating cancers | |
BR0309890A (pt) | Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação | |
AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
NO20053649L (no) | Kombinasjonsterapi | |
CR8850A (es) | Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales | |
BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
NO20045370L (no) | Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft | |
AR019699A1 (es) | Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico | |
BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
BRPI0518619A2 (pt) | mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica | |
BRPI0518062A (pt) | uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
BR0111683A (pt) | Remédios para doenças alérgicas e processo de produção do mesmo | |
AR064185A1 (es) | Composiciones y metodos para tratar las convulsiones | |
WO2008049903A3 (en) | Wide-area parasystemic treatment of skin related conditions | |
ES2211996T3 (es) | Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis. | |
BR0309569A (pt) | Vacinas em combinação que incluem polipeptìdeos imunogênicos de fator camp e gapc | |
NO20081415L (no) | Fremgangsmate for utforelse av en perkutan koronar intervensjon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |